奥尔梅沙坦: 360度的视角 适合一个血管激素受体阻断剂
Sadanand Shetty1, Anil Bhoraskar2, Banshi Saboo3
1Chairman and Managing Director, Sadanand Healthy Living Centre Ltd., Mumbai, Maharashtra, India.
The Journal of the Association of Physicians of India
|December 15, 2024
概括
奥尔梅沙坦是一种血管激素受体阻断剂 (ARB),有效降低血压 (BP) 并在高血压管理中提供器官保护. 它降低了心血管事件和心房的风险,改善了患者的治疗结果.
科学领域:
- 心脏病学和内科医学.
- 药理学和治疗学 药理学和治疗学
背景情况:
- 高血压 (HTN) 在印度造成了严重的健康负担,经常导致血压控制不良 (BP) 和高血压介导的器官损伤 (HMOD).
- 血管激素受体抑制剂 (ARBs) 是管理不同患者群体的高血压的关键一线药物.
研究的目的:
- 提供关于奥尔梅沙坦在治疗高血压方面的疗效的全面审查.
- 突出奥尔梅沙坦在降低血压和提供器官保护作用方面的双重作用.
主要方法:
- 对olmesartan现有的临床证据和研究进行系统审查.
- 对聚焦于奥尔梅沙坦对血压控制和器官损伤标志物的影响的研究分析.
- 对奥尔梅沙坦对微血管炎症,心脏和血管改造的影响以及临床结果的数据的检查.
主要成果:
- 奥尔梅沙坦在实现持续24小时降低血压方面表现出高效.
- 证据支持奥尔梅沙坦对高血压中介器官损伤的保护作用,包括减少微血管炎症,左心室缩,蛋白尿和血管硬.
- 奥尔梅沙坦已被证明可以降低中央大动脉血压,心脑血管事件和心房动.
结论:
- 奥尔梅沙坦是一种高效的抗高血压剂,可显著降低血压并保护器官.
- 与奥尔梅沙坦单片药片组合的可用性可以提高治疗遵守性,并有助于实现血压目标.
- 奥尔梅沙坦是全面高血压管理的有价值的治疗选择,既可以控制血压,也可以预防器官损伤.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
580
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
580
01:25Antihypertensive Drugs: Direct Renin Inhibitors
487
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
487
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
473
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
473
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
01:17Antihypertensive Drugs: Action of β1 Blockers
306
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
306